The legal library gives you easy access to the FTC’s case information and other official legal, policy, and guidance documents.
20003130: Michael A. Karp; CoreComm Limited
20003108: Isle of Capri Casinos, Inc.; Hilton Hotels Corporation
20003099: GTCR Fund VI, L.P.; Genesis Eldercare Corporation
20003078: Swiss Reinsurance Company; Industrial Life Insurance Company
20003068: Marsh & Mclennan Companies, Inc.; David A.Nadler
20003036: RCBA Strategic Partners, L.P.; CB Richard Ellis Services, Inc.
20003034: ATX Telecommunications Services, Inc.; Voyager.net, Inc.
Geneva Pharmaceuticals, Inc., In the Matter of
Harbour Group Investments, L.P., In the Matter of
Abbott Laboratories, In the Matter of
Abbott and Geneva Pharmaceuticals settled charges that the two firms entered into an illegal agreement to stop the marketing and development of a competing generic drug. According to the complaint, Abbott, manufacturer of Hytrin – the brand name for terazosin HCL, a prescription drug used to treat hypertension and benign prostatic hyperplasia, entered into an agreement with Geneva Pharmaceuticals whereby Abbott would pay Geneva millions of dollars not to market a generic version of Hytrin. The orders bars Abbott and Geneva, among other things, from entering into agreements in which a generic company agrees with a manufacturer of a branded drug to delay or stop the production of a competing drug.